Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q1 FY22 Earnings Presentation
20 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Aug 12, 2021
Slide 1: Investor Presentation cover letter to NSE
J. B. CHEMICALS & PHARMACEUTICALS LIMITED August 12, 2021 National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block-G, Bandra Kurla Complex Bandra (E) Mumbai 400 051 Stock Symbol: JBCHEPHARM Dear Sir, Subject: Investor Presentation Enclosed please find the presentation the Company proposes to
Slide 2: Q1 FY22 – Financial Results
Q1 FY22 – FINANCIAL RESULTS JB CHEMICALS AND PHARMACEUTICALS LIMITED
Slide 3: Disclaimer
Disclaimer The picture can't be display ed. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in a
Slide 4: Index
Index 4 8 14 Company Overview Q1 FY22 Financial Historical Financial Performance Performance 3
Slide 5: Company Overview
Company Overview J.B. CHEMICALS & PHARMACEUTICALS LTD.
Slide 6: Corporate Snapshot
Corporate Snapshot India field force Years of operations with Brands among top 300 Growth in chronic 40+ 5 21% #2,100+ expanded, significantly consistent track record brands, contributing therapies* in the over FY17-FY20 with across multiple over 70% of domestic domestic formulations therapy-focused
Slide 7: Domestic Formulations: Outperformance Driven by Strong Brands
Domestic Formulations: Outperformance Driven by Strong Brands Strong performance in chronic therapies JBCPL is the among the fastest Leadership position Chronic Therapies (%) Domestic Formulations* (INR cr) growing pharma companies in the covered markets 892 CAGR: 15% 797 675 24% 35% 588 Vs market g
Slide 8: International Business: Clearly Defined Businesses Across Geographies
International Business: Clearly Defined Businesses Across Geographies International Formulations CMO Direct presence in Russia Distributor relationships in the Leading global position in $ 4.6 bn Marquee global clients in and South Africa US, Asia, Africa and LatAm lozenges market opportunity pharma
Slide 9: Q1 FY22 Financial Performance
Q1 FY22 Financial Performance 8
Slide 10: CEO's Message
CEO’s Message Nikhil Chopra, CEO, JBCPL on the Q1 FY 22 business performance : “The organization continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry. Our new Go-To- Market(GTM) model has
Slide 11: Financial Overview Q1 FY22
Financial Overview Q1 FY 22 Revenues (INR cr) o The organization continues to perform well with revenue momentum continuing to remain strong 15% 2,043 o Highest ever quarterly revenue recorded during the first quarter of FY21, 1,775 despite lockdowns in key markets and supply chain challenges o Do
Slide 12: Financial Overview Q1 FY22
Financial Overview Q1 FY 22 Profit Before Tax (INR cr) 597 71% 349 o Profitability continues to remain strong despite normalized 0% cost base 157 157 o Other income in Q1 FY 22 is significantly lower by Rs. 9.7 cr on account of normalization of bond yields during Q1 FY 22 Q1 FY21 Q1 FY22 FY20 FY2
Slide 13: Revenue Analysis
Revenue Analysis o As per MAT June 21 IQVIA data, Domestic Formulations business continues to outpace industry growth rate Domestic Formulations* (INR cr) o As per IQVIA, JBCPL recorded growth of 22.1 % in Q1 FY 22 as compared to Q1 FY 21 12% o Big brands continue to support growth momentum with m
Slide 14: Q1 FY22 – Financial Performance
Q1 FY22 – Financial Performance Particulars (Rs. Crore) Q1 FY22 Q1 FY21 YoY Growth FY21 FY20 YoY Growth Revenue from Operations 606.0 522.3 16% 2,042.5 1,774.7 15% Cost of Goods Sold 216.5 186.3 16% 701.5 630.8 11% Employee Benefit Expenses 98.1 88.7 11% 340.6 322.9 5% Other Expenses 127.6 91.9 39%
Slide 15: Historical Financial Performance
Historical Financial Performance 14
Slide 16: Strong revenue growth
Strong revenue growth Domestic Formulations* (INR cr) Revenues (INR cr) International Business** (INR cr) CAGR:15% CAGR:13% 2,043 CAGR: 11% 892 1,775 1,127 797 1,643 942 954 675 1,413 816 588 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 EBITDA (INR cr) Profit After Tax (INR cr) Earnin
Slide 17: Financial Performance Analysis
Financial Performance Analysis Particulars FY18 FY19 FY20 FY21 Gross Margin 61.9% 63.7% 64.5% 65.7% Employee Cost/Revenues 17.8% 17.5% 18.2% 16.7% Operating Expenses/Revenues 28.8% 27.5% 25.0% 21.5% EBITDA Margin 15.4% 18.6% 21.3% 27.4% EBIT Margin 11.3% 15.2% 17.5% 24.1% Net Margin 10.0% 11.8% 15.3
Slide 18: Substantial improvements in shareholder returns and consistent cash generation
Substantial improvements in shareholder returns and consistent cash generation ROE (%) ROCE (%) Net Cash Position (INR cr) 663 42% 424 455 29% 392 24% 15% 25% 19% 13% 10% FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 Working Capital (INR cr) Working Capital (# days) Operating Cash Flow (INR cr) Free Cash
Slide 19: About J.B. Chemicals & Pharmaceuticals Limited
About J.B. Chemicals & Pharmaceuticals Limited J.B. Chemicals and Pharmaceuticals Limited (JBCPL) (BSE: 506943 | NSE: For further information, please JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hyp
Slide 20: Thank You
6 Thank You J.B. CHEMICALS & PHARMACEUTICALS LTD. of
J. B. Chemicals & Pharmaceuticals — Q1 FY22 Earnings Presentation on 6ix